Loading clinical trials...
Loading clinical trials...
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes
Conditions
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Acetylsalicylic Acid (ASA)
+3 more
Locations
140
United States
Los Angeles, California, United States
Washington D.C., District of Columbia, United States
Clearwater, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Start Date
December 16, 2015
Primary Completion Date
November 27, 2018
Completion Date
November 27, 2018
Last Updated
January 13, 2020
NCT07365345
NCT06518317
NCT04139616
NCT07045233
NCT05202977
NCT07411768
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions